Loading…
Vineet Laboratories (VINEETLAB)₹37.89−0.71%Pharmaceuticals
In the Dec 2025 quarter (standalone), Vineet Laboratories reported sales of ₹15.59 Cr, down 13.5% from Dec 2024, and net profit of ₹0.84 Cr. For the year to Mar 2025, sales were ₹74.71 Cr and net profit −₹19.96 Cr.
Company filings, standalone accounts; latest reported quarter Dec 2025
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57.00 | 37.39 | 43.23 | 32.53 | 36.89 | 23.76 | 18.89 | 18.03 | 14.03 | 7.42 | 17.37 | 15.59 |
| Expenses | 51.22 | 37.13 | 39.06 | 33.16 | 33.51 | 24.56 | 19.21 | 22.13 | 25.02 | 7.10 | 14.18 | 13.11 |
| Operating Profit | 5.83 | 0.27 | 4.18 | −0.65 | 3.43 | −0.80 | −0.32 | −4.14 | −11.07 | 0.32 | 3.19 | 2.49 |
| OPM % | 10.2% | 0.7% | 9.6% | −2.0% | 9.3% | −3.3% | −1.6% | −22.8% | −78.4% | 4.2% | 18.3% | 15.9% |
| Other Income | 0.02 | 0.02 | 0.00 | 0.00 | 0.40 | 0.36 | 0.19 | 0.02 | 1.37 | 0.01 | 0.00 | 0.04 |
| Interest | 0.36 | 0.97 | 1.03 | 1.09 | 1.73 | 1.15 | 0.98 | 0.96 | 0.91 | 0.60 | 2.18 | 1.10 |
| Depreciation | 0.63 | 0.62 | 0.62 | 0.64 | 0.68 | 0.62 | 0.63 | 0.63 | 0.67 | 0.64 | 0.64 | 0.64 |
| Profit before tax | 4.84 | −1.27 | 2.54 | −2.33 | 1.43 | −2.16 | −1.71 | −5.65 | −11.20 | −0.90 | 0.36 | 0.80 |
| Tax % | 26.8% | −2.3% | 4.7% | −11.1% | −34.0% | −1.8% | 7.0% | 0.5% | −6.2% | −4.4% | −8.1% | −3.7% |
| Net Profit | 3.54 | −1.24 | 2.41 | −2.06 | 1.91 | −2.12 | −1.82 | −5.70 | −10.51 | −0.86 | 0.39 | 0.84 |
| EPS (Rs) | 1.84 | −0.64 | 1.25 | −1.07 | 0.99 | −1.10 | −0.94 | −2.96 | −5.47 | −0.44 | 0.20 | 0.43 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 242 | 190 | 211 | 150 | 74.71 | 54.41 |
| Expenses | 0.00 | 234 | 177 | 204 | 142 | 90.62 | 59.41 |
| Operating Profit | 0.00 | 8.03 | 13.04 | 8.02 | 7.02 | −16.04 | −5.07 |
| OPM % | — | 3.4% | 7.0% | 3.6% | 4.8% | −22.0% | −9.3% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 1.42 |
| Interest | 0.00 | 3.01 | 1.99 | 2.99 | 5.01 | 4.01 | 4.79 |
| Depreciation | 0.00 | 2.01 | 2.01 | 2.01 | 3.01 | 2.01 | 2.59 |
| Profit before tax | 0.00 | 3.99 | 8.99 | 1.99 | 0.00 | −20.96 | −10.94 |
| Tax % | 0.0% | 56.0% | 29.1% | 38.0% | −183.0% | −3.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | — |
| Net Profit | 0.00 | 1.99 | 6.99 | 0.99 | 0.99 | −19.96 | −10.14 |
| EPS (Rs) | −0.10 | 0.92 | 3.45 | 0.64 | 0.53 | −10.50 | −5.28 |
| Dividend payout % | 0.0% | 0.0% | 13.9% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.41 | 8.98 | 8.98 | 8.99 | 8.99 | 8.98 |
| Reserves | 0.00 | 16.98 | 23.97 | 23.94 | 25.94 | 4.99 |
| Borrowings | 0.00 | 11.98 | 26.96 | 30.92 | 43.88 | 39.89 |
| Other Liabilities | 0.00 | 69.71 | 73.72 | 50.82 | 37.88 | 39.85 |
| Total Liabilities | 0.00 | 109 | 133 | 116 | 117 | 94.71 |
| Fixed Assets | 0.00 | 19.98 | 20.98 | 26.98 | 26.96 | 24.98 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 88.67 | 112 | 88.69 | 89.73 | 68.73 |
| Inventories | 0.00 | 40.14 | 44.15 | 46.20 | 49.17 | 50.15 |
| Trade receivables | 0.00 | 42.83 | 35.88 | 34.87 | 31.87 | 12.95 |
| Cash & equivalents | 0.00 | 1.99 | 17.99 | 0.99 | 0.00 | 0.99 |
| Total Assets | 0.00 | 109 | 133 | 116 | 117 | 94.71 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Cash from operating activity | 26.90 | 7.97 | −9.96 | −6.98 | 10.96 |
| Cash from investing activity | −7.97 | −3.99 | −6.98 | −1.99 | −2.99 |
| Cash from financing activity | 19.04 | 12.02 | 0.00 | 8.01 | −8.01 |
| Net cash flow | 38.13 | 16.06 | −16.06 | 0.00 | 0.00 |
| Capex | 0.00 | 0.00 | 7.66 | 2.80 | 1.06 |
| Free cash flow | 26.99 | 7.99 | −16.99 | −9.01 | 9.99 |
| CFO / OP % | 327.0% | 82.0% | −87.1% | −88.1% | −71.1% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor days | 65 | 70 | 61 | 78 | 65 |
| Inventory days | 74 | 110 | 99 | 159 | 261 |
| Days payable | 114 | 161 | 74 | 103 | 175 |
| Cash conversion cycle | 22 | 16 | 83 | 130 | 149 |
| Working capital days | 14 | −19 | 21 | 28 | −37 |
| ROCE % | 33.9% | 22.9% | 9.0% | 7.0% | −28.0% |
For the Dec 2025 quarter, Vineet Laboratories reported sales of ₹15.59 Cr, down 13.5% year on year and net profit of ₹0.84 Cr. The operating margin was 15.9%.
Vineet Laboratories' sales for the year to Mar 2025 were ₹74.71 Cr; over the last twelve months they were ₹54.41 Cr.
Net profit for the year to Mar 2025 was −₹19.96 Cr, and −₹10.14 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−5.28.
Vineet Laboratories reported borrowings of ₹39.89 Cr at Mar 2025, against cash and equivalents of ₹0.99 Cr.
Cash from operations was ₹10.96 Cr in the year to Mar 2025; after capital spending, free cash flow was ₹9.99 Cr.